Description
Rituximab which is a monoclonal antibody (a protein) and anti-neoplastic(anti-cancer) agent. This medicine binds specifically to the CD20 antigen located on pre-B and mature B lymphocytes (a type of white blood cells). CD20 is present on more than 90% of B-cell non-Hodgkin’s lymphomas (NHL), a cancer that starts in the lymphocytes. By doing so, it causes the malignant cells to die.